Printed From BioPortfolio.com
[Comment] Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers
10:57 EDT 26 Sep 2017 | The Lancet
Gastric and gastro-oesophageal cancers are the second leading cause of cancer death worldwide. Despite a concerted effort to characterise and understand the genomic landscape, only HER2 has been validated as a molecular target in the treatment of gastric and gastro-oesophageal cancer,1 highlighting the need to identify new therapeutic targets in the treatment for this disease.
Original Article: [Comment] Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers
